EF-1 α1/2 (Acetyl Lys146) rabbit pAb
活动价:
市场价:¥880.00
- 50μL
- 100μL
FAB2600379
- 产品信息
商品描述
靶点-Target
EF-1 α1/2
反应性
Human,Mouse,Rat
应用
WB,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Acetyl
MW(Observed)
51kD
推荐稀释比
WB 1:1000-2000;ELISA 1:5000-20000
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
Synthesized peptide derived from human EF-1 α1/2 (Acetyl Lys146)
特异性
This antibody detects endogenous levels of Human,Mouse,Rat EF-1 α1/2 (Acetyl Lys146)
基因名称
EEF1A1 EEF1A EF1A LENG7
蛋白名称
EF-1 α1/2 (Acetyl Lys146)
别名
Elongation factor 1-alpha 1;EF-1-alpha-1;Elongation factor Tu;EF-Tu;Eukaryotic elongation factor 1 A-1;eEF1A-1;Leukocyte receptor cluster member 7;
Organism-1
Human
基因ID-1
1915
SwissProt-1
P68104;Q05639;Q5VTE0
Organism-2
Mouse
基因ID-2
13627
SwissProt-2
P10126
Organism-3
Rat
基因ID-3
171361
SwissProt-3
P62630
背景
This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas, and the other isoform (alpha 2) is expressed in brain, heart and skeletal muscle. This isoform is identified as an autoantigen in 66% of patients with Felty syndrome. This gene has been found to have multiple copies on many chromosomes, some of which, if not all, represent different pseudogenes. [provided by RefSeq, Jul 2008],
细胞定位
Cytoplasm . Nucleus . Nucleus, nucleolus . Cell membrane . Colocalizes with DLC1 at actin-rich regions in the cell periphery (PubMed:19158340). Translocates together with ZPR1 from the cytoplasm to the nucleus and nucleolus after treatment with mitogens (PubMed:8650580). Localization at the cell membrane depends on EEF1A1 phosphorylation status and the presence of PPP1R16B (PubMed:26497934). .





